SCHEMBL4603764

SCHEMBL4603764

Cc1nc(Cl)c2ccccc2n1.c1ccc(CNCc2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
APP P05067 3/20 0.49
PDE5A O76074 1/20 0.49
DRD4 P21917 1/20 0.48
DRD3 P35462 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
RAD52 P43351 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
BCHE P06276 2/20 0.43
ACHE P22303 2/20 0.43
LMNA P02545 2/20 0.43
PKM P14618 1/20 0.43
UBE2N P61088 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RCE1 Q9Y256 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29461212 0.84 TDP1 (0.54) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL856788 0.84 TDP1 (0.54) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL4602308 0.77 MAPT (0.49) MAPTAPPPDE5ADRD4DRD3
SCHEMBL3977315 0.75 RAD52 (0.71) MAPTAPPPDE5AKDM4EALDH1A1
SCHEMBL12176179 0.73 APP (0.71) MAPTAPPPDE5AKDM4EALDH1A1
SCHEMBL4603879 0.72 ALDH1A1 (0.60) ALDH1A1RAD52KMT2APOLB
Benzene SCHEMBL11697595 0.70 MEN1 (0.78) MAPTKDM4EKMT2ABCHEPKM
SCHEMBL5799878 0.70 MEN1 (0.78) MAPTKDM4EKMT2ABCHEPKM
SCHEMBL1654 0.70 MEN1 (0.78) MAPTKDM4EKMT2ABCHEPKM
SCHEMBL3605345 0.69 DRD4 (0.46) MAPTDRD4DRD3L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1915351-A1 QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT SCHERING CORPORATION (US) 2008-04-30 EP disclosed
WO-2007011618-A1 QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT SCHERING CORPORATION (US) 2007-01-25 WO disclosed
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment TP53, TP53BP1, ACIN1 MAPT 3828/4885APP 4431/4885PDE5A 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.